Paper41501375
The functional imperative in high-grade glioma.
Goh LSH and 5 others. Exp Mol Med, 2026. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. The functional imperative in high-grade glioma. Papers, record 41501375. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41501375
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glioma | Major topic |
| Brain Neoplasms | Major topic |
| Precision Medicine | Major topic |
| Humans | |
| Neoplasm Grading | |
| Animals | |
| Biomarkers, Tumor | |
| Molecular Targeted Therapy |
Source PubMed
References114
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17051156 | Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. | Nature | 2006 | https://conductscience.org/library/papers/17051156 | PubMed |
| 2 | 30153097 | CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/30153097 | PubMed |
| 3 | 38480922 | Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results. | Nat Med | 2024 | https://conductscience.org/library/papers/38480922 | PubMed |
| 4 | 31327527 | An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. | Cell | 2019 | https://conductscience.org/library/papers/31327527 | PubMed |
| 5 | 19720927 | Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19720927 | PubMed |
| 6 | 38664630 | A qualitative evaluation of factors influencing Tumor Treating fields (TTFields) therapy decision making among brain tumor patients and physicians. | BMC Cancer | 2024 | https://conductscience.org/library/papers/38664630 | PubMed |
| 7 | 39657679 | Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy. | Cell Stem Cell | 2025 | https://conductscience.org/library/papers/39657679 | PubMed |
| 8 | 38390032 | Reassessing the efficacy of bevacizumab in newly diagnosed glioblastoma: A systematic review and external pseudodata-based analysis. | Neurooncol Adv | 2024 | https://conductscience.org/library/papers/38390032 | PubMed |
| 9 | 20472883 | mTOR signaling in glioblastoma: lessons learned from bench to bedside. | Neuro Oncol | 2010 | https://conductscience.org/library/papers/20472883 | PubMed |
| 10 | 36567957 | Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature. | Neurooncol Adv | 2022 | https://conductscience.org/library/papers/36567957 | PubMed |
| 11 | 30018133 | Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study. | Oncologist | 2018 | https://conductscience.org/library/papers/30018133 | PubMed |
| 12 | 7001230 | Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. | N Engl J Med | 1980 | https://conductscience.org/library/papers/7001230 | PubMed |
| 13 | 35849035 | Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. | Neuro Oncol | 2023 | https://conductscience.org/library/papers/35849035 | PubMed |
| 14 | 33414553 | Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. | Nat Genet | 2021 | https://conductscience.org/library/papers/33414553 | PubMed |
| 15 | 16697959 | Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. | Cancer Cell | 2006 | https://conductscience.org/library/papers/16697959 | PubMed |
| 16 | 34250400 | High-Throughput Drug Screening and Multi-Omic Analysis to Guide Individualized Treatment for Multiple Myeloma. | JCO Precis Oncol | 2021 | https://conductscience.org/library/papers/34250400 | PubMed |
| 17 | 20129251 | Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. | Cancer Cell | 2010 | https://conductscience.org/library/papers/20129251 | PubMed |
| 18 | 216819 | Quality and duration of survival in glioblastoma multiforme. Combined surgical, radiation, and lomustine therapy. | JAMA | 1979 | https://conductscience.org/library/papers/216819 | PubMed |
| 19 | 23333277 | Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. | Cell Rep | 2013 | https://conductscience.org/library/papers/23333277 | PubMed |
| 20 | 34422657 | Uncovering Spatiotemporal Heterogeneity of High-Grade Gliomas: From Disease Biology to Therapeutic Implications. | Front Oncol | 2021 | https://conductscience.org/library/papers/34422657 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42882426 | Stromal Remodeling of the Cytokine Secretome Reveals a Chemokine Core Across Breast Cancer and Glioma 3D Cell Culture Models. | Cells | 2026 | https://conductscience.org/library/papers/42882426 | PubMed |
| 42591582 | miR-506-5p targets MAPK7 to impede glioma growth and invasion through suppressing epithelial-mesenchymal transition and matrix metalloproteinases. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42591582 | PubMed |
| 42042543 | Molecular Oncodiagnostics in Precision Oncology: Integrating Tumor Transcriptomics, Patient Pharmacogenetics, and Ex Vivo Chemoresistance Testing to Improve Individual Chemotherapy Response. | J Pers Med | 2026 | https://conductscience.org/library/papers/42042543 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41501375
GET https://conductscience.org/api/papers/v1/41501375/references?page=2